A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Takeshi Suzuki, Yasutaka Sukawa, Chiyo K. Imamura, Toshiki Masuishi, Hironaga Satake, Yosuke Kumekawa, Shinsuke Funakoshi, Masahito Kotaka, Yoshiki Horie, Sadayuki Kawai, Hiroyuki Okuda, Tetsuji Terazawa, Chihiro Kondoh, Ken Kato, Kenichi Yoshimura, Hideki Ishikawa, Yasuo Hamamoto, Narikazu Boku, Hiromasa Takaishi, Takanori Kanai

研究成果: Article査読

5 被引用数 (Scopus)

抄録

To improve the tolerability and maintain sufficient efficacy of regorafenib, we conducted a phase II study of regorafenib with a lower starting dose of 120 mg/day for patients with refractory metastatic colorectal cancer. Using this dose-escalation strategy, the disease control rate for the 68 evaluable patients was lower than that in our statistical hypothesis, and a relationship of unbound exposure with toxicity was observed.

本文言語English
ページ(範囲)13-21.e3
ジャーナルClinical Colorectal Cancer
19
1
DOI
出版ステータスPublished - 2020 3

ASJC Scopus subject areas

  • 腫瘍学
  • 消化器病学

フィンガープリント

「A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル